ECSP034618A - Nuevos compuestos para usarse como inhibidores de proteasa vih - Google Patents
Nuevos compuestos para usarse como inhibidores de proteasa vihInfo
- Publication number
- ECSP034618A ECSP034618A EC2003004618A ECSP034618A ECSP034618A EC SP034618 A ECSP034618 A EC SP034618A EC 2003004618 A EC2003004618 A EC 2003004618A EC SP034618 A ECSP034618 A EC SP034618A EC SP034618 A ECSP034618 A EC SP034618A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- heterocyclyl
- aryl
- sulfonyl
- oxycarbonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 abstract 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 abstract 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- -1 heterocyclyl sulfonium Chemical compound 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 150000002485 inorganic esters Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000002895 organic esters Chemical class 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se revelan los compuestos de la formula general y las sales farmacéutica mente aceptables de los mismos en donde R1 es H, hidroxilo o NHR2 en donde R2 es H, alquilo, alquenilo, alquinilo, arilalquilo, heterocicliaquilo, cicloalquilo, alquil caronilo, cicloalquilo, alquil, carbonilo, heterociclil alquil carbonilo, alquil oxi carbonilo, aril alquil oxi carbonilo, heterociclil alquil oxi carbonilo, arilo, heterociclilo, sulfonilo, alquil sulfonilo, aril sulfonilo, heterociclil sulfonilo, heterociclil sulfonio o un grupo de fórmula en donde X o 0 ó S y R7 y R8 independietemente son H, alquilo, arilo, heterociclilo, aril alquilo, heterociclil alquilo o R7 y R8 junto con el átomo de nitrógeno al que están unidos forman un anillo saturado que opcionalmente contienen además un teteroátomo o un grupo en donde cuando n=0, y representa 0 ó S y R10 es H, alquilo, aril alquilo, heterociclil alquilo, arilo heterociclilo o cuando n=1, Y representa N, R9 es H o alquilo y R10 H, alquilo, aril alquilo, heterociclil alquilo, arilo, heterociclilo o R9 y R10 junto con el hetroátomo al que estan unidos forman un heterociclo, y R6 es alquilo, aril alquilo, heterociclil alquilo, alquil oxi alquilo, hidroxi alquilo, amino alqulo, fluoro alquilo y R13 es H o el residuo de un éster inorgánico y orgánico y R15 es ailo, con la excepción que, si R3, R4 y R5 son melino, R6 es terebutilo, R13 es H y si R15 es fenilo R2 no es bencil oxicarbonilo ni 2-quinolina carbonilo. Los compuestos de fórmula I son potentes inhibidores de la VIH aspartil proteasa y se pueden usar en el tratamiento de enfermedades relacionadas con VIH.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0028483.6A GB0028483D0 (en) | 2000-11-22 | 2000-11-22 | Hydroxyethylamine HIV protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034618A true ECSP034618A (es) | 2003-06-25 |
Family
ID=9903670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004618A ECSP034618A (es) | 2000-11-22 | 2003-05-21 | Nuevos compuestos para usarse como inhibidores de proteasa vih |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6472404B1 (es) |
| EP (1) | EP1339692A1 (es) |
| JP (1) | JP2004520283A (es) |
| KR (1) | KR20030060953A (es) |
| CN (1) | CN1476436A (es) |
| AR (1) | AR031763A1 (es) |
| AU (2) | AU2002229546B2 (es) |
| BG (1) | BG107839A (es) |
| BR (1) | BR0115566A (es) |
| CA (1) | CA2428459A1 (es) |
| CZ (1) | CZ20031667A3 (es) |
| EC (1) | ECSP034618A (es) |
| GB (1) | GB0028483D0 (es) |
| GT (1) | GT200100233A (es) |
| HU (1) | HUP0303007A2 (es) |
| IL (1) | IL155573A0 (es) |
| MA (1) | MA26966A1 (es) |
| MX (1) | MXPA03004534A (es) |
| NO (1) | NO20032290L (es) |
| NZ (1) | NZ525550A (es) |
| PA (1) | PA8533401A1 (es) |
| PE (1) | PE20020610A1 (es) |
| PL (1) | PL366704A1 (es) |
| RU (1) | RU2265016C2 (es) |
| SK (1) | SK7602003A3 (es) |
| UY (1) | UY27033A1 (es) |
| WO (1) | WO2002042277A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4953297B2 (ja) * | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| WO2009119534A1 (ja) * | 2008-03-26 | 2009-10-01 | 第一三共株式会社 | 新規テトラヒドロイソキノリン誘導体 |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8927913D0 (en) | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| MX9308016A (es) * | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene. |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
-
2000
- 2000-11-22 GB GBGB0028483.6A patent/GB0028483D0/en not_active Ceased
-
2001
- 2001-11-12 AU AU2002229546A patent/AU2002229546B2/en not_active Ceased
- 2001-11-12 IL IL15557301A patent/IL155573A0/xx unknown
- 2001-11-12 AU AU2954602A patent/AU2954602A/xx active Pending
- 2001-11-12 KR KR10-2003-7006907A patent/KR20030060953A/ko not_active Ceased
- 2001-11-12 MX MXPA03004534A patent/MXPA03004534A/es active IP Right Grant
- 2001-11-12 HU HU0303007A patent/HUP0303007A2/hu unknown
- 2001-11-12 BR BR0115566-0A patent/BR0115566A/pt not_active IP Right Cessation
- 2001-11-12 NZ NZ525550A patent/NZ525550A/en unknown
- 2001-11-12 CN CNA018192890A patent/CN1476436A/zh active Pending
- 2001-11-12 RU RU2003117468/04A patent/RU2265016C2/ru not_active IP Right Cessation
- 2001-11-12 CA CA002428459A patent/CA2428459A1/en not_active Abandoned
- 2001-11-12 SK SK760-2003A patent/SK7602003A3/sk unknown
- 2001-11-12 WO PCT/EP2001/013068 patent/WO2002042277A1/en not_active Ceased
- 2001-11-12 PL PL01366704A patent/PL366704A1/xx not_active Application Discontinuation
- 2001-11-12 JP JP2002544412A patent/JP2004520283A/ja active Pending
- 2001-11-12 CZ CZ20031667A patent/CZ20031667A3/cs unknown
- 2001-11-12 EP EP01990405A patent/EP1339692A1/en not_active Withdrawn
- 2001-11-20 US US09/999,082 patent/US6472404B1/en not_active Expired - Fee Related
- 2001-11-21 AR ARP010105431A patent/AR031763A1/es unknown
- 2001-11-21 UY UY27033A patent/UY27033A1/es not_active Application Discontinuation
- 2001-11-21 GT GT200100233A patent/GT200100233A/es unknown
- 2001-11-21 PA PA20018533401A patent/PA8533401A1/es unknown
- 2001-11-22 PE PE2001001170A patent/PE20020610A1/es not_active Application Discontinuation
-
2003
- 2003-05-21 NO NO20032290A patent/NO20032290L/no unknown
- 2003-05-21 EC EC2003004618A patent/ECSP034618A/es unknown
- 2003-05-22 MA MA27172A patent/MA26966A1/fr unknown
- 2003-05-22 BG BG107839A patent/BG107839A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY27033A1 (es) | 2002-06-20 |
| AU2002229546B2 (en) | 2006-05-04 |
| CA2428459A1 (en) | 2002-05-30 |
| RU2265016C2 (ru) | 2005-11-27 |
| EP1339692A1 (en) | 2003-09-03 |
| KR20030060953A (ko) | 2003-07-16 |
| NO20032290D0 (no) | 2003-05-21 |
| US6472404B1 (en) | 2002-10-29 |
| SK7602003A3 (en) | 2004-01-08 |
| PL366704A1 (en) | 2005-02-07 |
| NO20032290L (no) | 2003-05-21 |
| BR0115566A (pt) | 2003-09-30 |
| PE20020610A1 (es) | 2002-07-13 |
| AR031763A1 (es) | 2003-10-01 |
| GB0028483D0 (en) | 2001-01-10 |
| JP2004520283A (ja) | 2004-07-08 |
| CN1476436A (zh) | 2004-02-18 |
| WO2002042277A1 (en) | 2002-05-30 |
| CZ20031667A3 (cs) | 2004-01-14 |
| MXPA03004534A (es) | 2003-09-10 |
| NZ525550A (en) | 2004-11-26 |
| HUP0303007A2 (hu) | 2003-12-29 |
| AU2954602A (en) | 2002-06-03 |
| PA8533401A1 (es) | 2002-10-31 |
| GT200100233A (es) | 2002-07-04 |
| IL155573A0 (en) | 2003-11-23 |
| BG107839A (bg) | 2004-06-30 |
| RU2003117468A (ru) | 2005-01-27 |
| MA26966A1 (fr) | 2004-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP055636A (es) | Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa | |
| ECSP078004A (es) | PREPARACIÓN y USO DE COMPUESTOS COMO INHIBIDORES DE PROTEASAS | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| PE20200665A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| AR058562A1 (es) | Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1 | |
| AR061371A1 (es) | Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas. | |
| PE20040479A1 (es) | Inhibidores de proteasa del vih y composiciones que los contienen | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
| UY27357A1 (es) | Nuevos agentes antidiabéticos . | |
| AR056838A1 (es) | Derivados de 1,2,5-tiadiazol | |
| AR055774A1 (es) | Fenilacetamidas apropiadas como inhibidores de proteina quinasa | |
| PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos | |
| AR042827A1 (es) | Compuestos de furano condensados | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR041246A1 (es) | Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene | |
| ECSP045420A (es) | Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos | |
| AR044177A1 (es) | Proceso para la preparacion de trans-isomeros de derivados de la difenilazetidinona | |
| AR059030A1 (es) | Combinacion de derivados de triazina y estimuladores de la secrecion de insulina | |
| AR051391A1 (es) | Compuesto de pirrolidina antagonista del receptor h3; composicion farmaceutica que lo comprende, su uso para preparar un medicamento para el tratamiento de enfermedades neurologicas y un procedimiento para su elaboracion. | |
| AR049433A1 (es) | Derivados de naftalina | |
| AR040928A1 (es) | Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas | |
| UY26847A1 (es) | Derivados de la pirrolidina | |
| AR044540A1 (es) | 1,4-benzodiazepinas sustituidas y usos de las mismas | |
| AR043563A1 (es) | Inhibidores de catepsina s | |
| AR054992A1 (es) | Pteridinas sustituidas y uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias |